日本高潮视频在线观看-亚洲中文字幕永不卡-精品亚洲一区二区三区-伦理片夜夜躁狠狠躁日日躁-日本最新免费不卡二区-国产精品口爆一区二区三区-av一区二区三区高清-大鸡巴疯狂抽插小穴视频-日韩中文国产在线观看免费视频

Your Good Partner in Biology Research

重組蛋白

產(chǎn)品名稱 貨號 規(guī)格
Recombinant Yersinia pseudotuberculosis serotype O:1b Ribonuclease H (rnhA) CSB-YP409840YAN
CSB-EP409840YAN
CSB-BP409840YAN
CSB-MP409840YAN
CSB-EP409840YAN-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Yersinia pseudotuberculosis serotype O:1b Urease subunit gamma (ureA) CSB-YP409841YAN
CSB-EP409841YAN
CSB-BP409841YAN
CSB-MP409841YAN
CSB-EP409841YAN-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Yersinia pseudotuberculosis serotype O:1b Urease accessory protein UreE (ureE) CSB-YP409842YAN
CSB-EP409842YAN
CSB-BP409842YAN
CSB-MP409842YAN
CSB-EP409842YAN-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Yersinia pseudotuberculosis serotype O:1b UPF0271 protein YpsIP31758_1117 (YpsIP31758_1117) CSB-YP409843YAN
CSB-EP409843YAN
CSB-BP409843YAN
CSB-MP409843YAN
CSB-EP409843YAN-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Yersinia pseudotuberculosis serotype O:1b Autonomous glycyl radical cofactor (grcA) CSB-YP409844YAN
CSB-EP409844YAN
CSB-BP409844YAN
CSB-MP409844YAN
CSB-EP409844YAN-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Yersinia pseudotuberculosis serotype O:1b DNA repair protein recO (recO) CSB-YP409845YAN
CSB-EP409845YAN
CSB-BP409845YAN
CSB-MP409845YAN
CSB-EP409845YAN-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Yersinia pseudotuberculosis serotype O:1b Peptidase B (pepB) CSB-YP409846YAN
CSB-EP409846YAN
CSB-BP409846YAN
CSB-MP409846YAN
CSB-EP409846YAN-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Yersinia pseudotuberculosis serotype O:1b GTPase Der (der) CSB-YP409847YAN
CSB-EP409847YAN
CSB-BP409847YAN
CSB-MP409847YAN
CSB-EP409847YAN-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Yersinia pseudotuberculosis serotype O:1b Multidrug resistance protein MdtC (mdtC), partial CSB-YP409848YAN
CSB-EP409848YAN
CSB-BP409848YAN
CSB-MP409848YAN
CSB-EP409848YAN-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Yersinia pseudotuberculosis serotype O:1b Dihydrodipicolinate synthase (dapA) CSB-YP409849YAN
CSB-EP409849YAN
CSB-BP409849YAN
CSB-MP409849YAN
CSB-EP409849YAN-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Yersinia pseudotuberculosis serotype O:1b Periplasmic nitrate reductase (napA), partial CSB-YP409850YAN
CSB-EP409850YAN
CSB-BP409850YAN
CSB-MP409850YAN
CSB-EP409850YAN-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Yersinia pseudotuberculosis serotype O:1b N-acetylmannosamine kinase (nanK) CSB-YP409851YAN
CSB-EP409851YAN
CSB-BP409851YAN
CSB-MP409851YAN
CSB-EP409851YAN-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Yersinia pseudotuberculosis serotype O:1b DNA ligase (ligA), partial CSB-YP409852YAN
CSB-EP409852YAN
CSB-BP409852YAN
CSB-MP409852YAN
CSB-EP409852YAN-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Human RRN3-like protein 1 CSB-YP409853HU
CSB-EP409853HU
CSB-BP409853HU
CSB-MP409853HU
CSB-EP409853HU-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Human Putative CDC37-like protein ENSP00000350273 CSB-YP409854HU
CSB-EP409854HU
CSB-BP409854HU
CSB-MP409854HU
CSB-EP409854HU-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Human Putative speedy protein-like protein 3 CSB-YP409855HU
CSB-EP409855HU
CSB-BP409855HU
CSB-MP409855HU
CSB-EP409855HU-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Human Putative protein FAM86A-like 3 CSB-YP409856HU
CSB-EP409856HU
CSB-BP409856HU
CSB-MP409856HU
CSB-EP409856HU-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Human Putative tubulin beta chain-like protein ENSP00000290377 CSB-YP409857HU
CSB-EP409857HU
CSB-BP409857HU
CSB-MP409857HU
CSB-EP409857HU-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Human Protein shisa-7 (SHISA7), partial CSB-YP409858HU
CSB-EP409858HU
CSB-BP409858HU
CSB-MP409858HU
CSB-EP409858HU-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Human Putative tripartite motif-containing protein 64C (TRIM64C) CSB-YP409859HU
CSB-EP409859HU
CSB-BP409859HU
CSB-MP409859HU
CSB-EP409859HU-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開發(fā)過程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長度(全長或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見問題。您可以單擊以下鏈接查看。http://m.bdspa.cn/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對CUSABIO的蛋白質(zhì)有任何疑問,涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們在線留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>



×